Dr. Tyler Curiel is a physician-scientist with clinical expertise in phase I
experimental therapeutics and gynecologic cancers. His laboratory
expertise is in human immunology with an emphasis on understanding the
immunopathologic basis of human diseases including cancer, infections
He has significant administrative expertise as past
chief of two different academic divisions of hematology and medical
oncology, director of a general clinical research center and executive
director of an NCI-designated cancer center. He translates his groups
discoveries into novel clinical trials.
Hasty P, Livi CB, Dodds SG, Jones D, Strong R, Javors M, Fischer KE,
Sloane L, Murthy K, Hubbard G, Sun L, Hurez V, Curiel TJ, Sharp ZD. eRapa restores a normal life span in a FAP mouse model. Cancer Prev Res (Phila). 2014 Jan;7(1):169-78.
Tomihara K, Curiel TJ, Zhang B. Optimization of immunotherapy in elderly cancer patients. Crit Rev Oncog. 2013;18(6):573-83.
Hasty P, Sharp ZD, Curiel TJ, Campisi J. mTORC1 and p53: clash of the gods? Cell Cycle. 2013 Jan 1;12(1):20-5.
Wang L, Fan J, Chen S, Zhang Y, Curiel TJ, Zhang B. Graft-versus-host disease is enhanced by selective CD73 blockade in mice. PLoS One. 2013;8(3):e58397.
Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Vadlamudi RK. Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res. 2011 Apr 15;17(8):2250-9.